A recombinant tumor necrosis factor ? inhibitor.
Associated with infections and should be used with caution in patients predisposed to infection or with recurrent infections.
Binds soluble TNF and lymphotoxin.
Administered subcutaneously 1-2 times weekly.
Reduces signs and symptoms and delays structural damage in patients with rheumatoid arthritis.
Site reactions in up to 42% of patients and is the most common adverse effect.
Demonstrated efficacy in rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease.
Utilized to treat psoriasis in adults and reduces severity of disease in children and adolescents with moderate to severe plaque psoriasis.
Adverse effects include site injection reactions, upper respiratory tract symptoms, and headaches.
Can cause inflammatory lung injury.
Slightly increased risk of infection with common and unusual organisms.
Associated with a lower rate of infections compared to other TNF inhibitors.
Higher risk of bacterial infections sch as listeria, norcardia, or various mycobacteria.
In juvenile idiopathic arthritis associated with a 30% improvement from baseline in more than 70% of patients (Lovell DJ et al).